Vaxart Inc (VXRT)

Currency in USD
0.5660
+0.0010(+0.18%)
Closed·
VXRT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.51000.5700
52 wk Range
0.26060.8449
Key Statistics
Prev. Close
0.5649
Open
0.57
Day's Range
0.51-0.57
52 wk Range
0.2606-0.8449
Volume
228.51K
Average Volume (3m)
797.35K
1-Year Change
-24.149%
Book Value / Share
0.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VXRT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.0000
Upside
+430.04%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Vaxart Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Vaxart Inc Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Vaxart Inc Earnings Call Summary for Q3/2025

  • Vaxart Inc. reported Q3 2025 revenue of $72.4 million, up from $6.4 million year-over-year, though stock rose only 0.66% to $0.3651 in premarket trading
  • Cash runway extended to Q2 2027 through strategic partnership with Dynavax Technologies, expected to yield up to $700 million in fees and royalties
  • Company faces significant challenge with stop-work order on key BARDA contract while advancing plans for new norovirus vaccine trial in 2026
  • Top-line data from Sentinel cohort study expected in Q1 2026 as company continues exploring partnerships for norovirus, HPV, and flu programs
  • CEO Steven Lo emphasized transformative potential of oral pill vaccine platform designed to generate both systemic and mucosal immunity
Last Updated: 2025-11-13, 05:32 p/m
Read Full Transcript

Compare VXRT to Peers and Sector

Metrics to compare
VXRT
Peers
Sector
Relationship
P/E Ratio
−2.7x−2.1x−0.5x
PEG Ratio
−0.06−0.020.00
Price/Book
5.1x3.1x2.6x
Price / LTM Sales
0.9x184.4x3.3x
Upside (Analyst Target)
-415.3%47.0%
Fair Value Upside
Unlock13.1%5.9%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.0000
(+430.04% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
B.Riley
Buy2.00+253.36%2.50MaintainMar 27, 2025
Oppenheimer
Buy4.00+606.71%-MaintainFeb 24, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.04 / -0.07
Revenue / Forecast
72.40M / 21.15M
EPS Revisions
Last 90 days

VXRT Income Statement

People Also Watch

15.1400
TNXP
+0.26%
4.2000
ATOS
+6.60%
0.752
MVIS
+7.59%
2.2200
IBIO
+5.21%
1.410
OCGN
0.00%

FAQ

What Is the Vaxart (VXRT) Stock Price Today?

The Vaxart stock price today is 0.5660

What Stock Exchange Does Vaxart Trade On?

Vaxart is listed and trades on the OTC Markets.

What Is the Stock Symbol for Vaxart?

The stock symbol for Vaxart is "VXRT."

What Is the Vaxart Market Cap?

As of today, Vaxart market cap is 135.8300M.

What Is Vaxart's Earnings Per Share (TTM)?

The Vaxart EPS (TTM) is -0.22.

When Is the Next Vaxart Earnings Date?

Vaxart will release its next earnings report on Mar 19, 2026.

From a Technical Analysis Perspective, Is VXRT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Vaxart Stock Split?

Vaxart has split 2 times.

How Many Employees Does Vaxart Have?

Vaxart has 105 employees.

What is the current trading status of Vaxart (VXRT)?

As of Feb 16, 2026, Vaxart (VXRT) is trading at a price of 0.5660, with a previous close of 0.5649. The stock has fluctuated within a day range of 0.5100 to 0.5700, while its 52-week range spans from 0.2606 to 0.8449.

What Is Vaxart (VXRT) Price Target According to Analysts?

The average 12-month price target for Vaxart is USD3.0000, with a high estimate of USD4 and a low estimate of USD2. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +430.04% Upside potential.

What Is the VXRT Premarket Price?

VXRT's last pre-market stock price is 0.5900. The pre-market share volume is 20.0000, and the stock has decreased by 0.0251, or 4.4400%.

What Is the VXRT After Hours Price?

VXRT's last after hours stock price is 0.7822, the stock has decreased by -0.0178, or -2.2300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.